Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.
List view / Grid view
Operation Pangea has revealed a large number of falsified coronavirus treatments, while the MHRA has seized 871,616 doses of other unlicensed medicines.
A study has reported that millions currently taking benzodiazepines to help them sleep would not hear a fire alarm, thus warning of possible dangers...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients…
Insomnia treatment market faces steep decline to 2016, but new drugs will aid recovery, says GlobalData
17 February 2015 | By GlobalData
Insomnia drug sales will fall rapidly from $2.1 billion in 2013 to $1.4 billion by 2016, before steadily recovering to $1.8 billion by 2023, driven by the launch of two products, Merck & Co.’s Belsomra and Eisai’s E-2006, and an increase in the prevalent cases of insomnia, says research and…
Merck receives Complete Response Letter for Suvorexant, Merck’s investigational medicine for insomnia
1 July 2013 | By Merck
“We will evaluate the requests outlined in the Complete Response Letter..."
Merck announces FDA acceptance of New Drug Application for Suvorexant, an investigational insomnia medicine
8 November 2012 | By Merck
Merck announced that the NDA for suvorexant has been accepted for standard review...
10 September 2012 | By Merck
Merck remains on target to file a New Drug Application with the FDA in 2012...
New Phase III data showed Merck’s investigational insomnia medicine suvorexant improved patients’ ability to fall asleep and stay asleep
13 June 2012 | By Merck
New data from two pivotal Phase III trials...